{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"97"}],"units":"Participants"}],"description":"Antibody titers specific to the tisagenlecleucel molecule prior to and following infusion. Percentage of participants who tested positive for anti-mCAR19 antibodies at any time post-baseline. A participant was only defined as positive for tisagenlecleucel treatment-induced or -boosted anti-mCAR19 antibodies when the anti-mCAR19 antibody median fluorescence intensity (MFI) at any time post-infusion was at least 2.28-fold higher than pre-infusion levels for patients whose baseline status was positive (boosted) or if the baseline status was negative, but any post-baseline interpretation was positive (induced).","groups":[{"description":"All participants who were enrolled in the study","id":"OG000","title":"CTL019"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Set: The Safety set comprised of all participants who received tisagenlecleucel.","reportingStatus":"POSTED","timeFrame":"at any time post-baseline, up to 24 months post-infusion","title":"Humoral Immunogenicity: Number of Participants With Anti-mCAR19 Antibodies, Per IRC Assessment","type":"SECONDARY","unitOfMeasure":"Participants"}